Rocket One is the same Nevada issuer that spent nearly a decade as Hoth Therapeutics, and the mid-year rename does not create a semiconductor franchise so much as it relabels a pre-revenue balance sheet around two exclusive university licenses. Those licenses cover a nanomagnetic matrix-multiplier architecture and related spintronic memory aimed at low-power, radiation-tolerant computing for data centers, defense platforms, and orbit. The rights arrived with a mid-single-digit royalty schedule and a diligence clock, not a fabricated chip, a foundry slot, or a paying customer. The equity debate is whether that paper estate, plus a leftover dermatology and oncology pipeline parked in a wholly owned subsidiary, is worth more than the cash the company keeps raising by selling common stock into a thin Nasdaq Capital Market tape.
Cash at mid-year sat near $8 million only because equity issuance refilled the treasury after a first-quarter trough. An at-the-market program run through H.C. Wainwright and an April registered direct rebuilt liquidity while the income statement still printed a wider operating loss and zero revenue. Nasdaq restored bid-price compliance in late June, then mailed a fresh deficiency notice in early August after another stretch below the one-dollar floor. The listing clock now runs into early next year, and a reverse split sits among the stated options. Dilution is not a side effect of the pivot. It is how the pivot is funded.
Swarm Stage, a drone-swarm threat-emulation pitch aimed at United States counter-drone training, is the nearest thing to a shippable product, and management is careful to say that availability is not a defense contract. The Virginia Commonwealth University devices remain unbuilt and unqualified for any commercial or government program. The old HT-001 skin-toxicity study continues to enroll under the biotech subsidiary. The next several quarters resolve a simple question: does any license, software demo, or leftover clinic convert into a paid relationship or a working device before the bid-price cure and the remaining ATM capacity force another recap.